Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France.
Ann Oncol. 2010 Oct;21 Suppl 7:vii59-62. doi: 10.1093/annonc/mdq371.
Treatment of renal cell carcinoma has dramatically changed in the past 5 years, with the approval of six new drugs since 2006. Although treatment algorithms have been reported and updated every year since 2006, the choice of targeted therapy is not always easy. Selecting a targeted agent in metastatic renal cell carcinoma should take into account various parameters, including the status of the disease, the histology, the status of the patient and finally the availability of the drugs in each country. In addition, in front of every patient, the physician will need to raise important questions such as whether the patient should be treated, should receive surgery and also what is his prognosis. The different options are described here.
过去 5 年来，肾癌的治疗发生了显著变化，自 2006 年以来已有 6 种新药获得批准。虽然自 2006 年以来每年都有报告和更新治疗算法，但靶向治疗的选择并不总是那么容易。在转移性肾细胞癌中选择靶向药物时，应考虑各种参数，包括疾病状态、组织学、患者状态以及每种药物在每个国家的可获得性。此外，对于每位患者，医生都需要提出一些重要问题，例如患者是否应该接受治疗、是否应进行手术以及他的预后如何。这里描述了不同的选择。
